MASS GENERAL BRIGHAM - Key Persons
Job Titles:
- Chief Executive Officer of the Biopharma Commercial Unit at Sumitomo Pharma America
- Chief Executive Officer, Biopharma Commercial Unit at Sumitomo Pharma America
Adele Gulfo has served as chief executive officer of the Biopharma Commercial Unit at Sumitomo Pharma America since the Company's formation in 2023, with oversight of the Company's commercial products APTIOM®, GEMTESA®, LATUDA®, MYFEMBREE®, ORGOVYX®, and RETHYMIC®.
Job Titles:
- Managing Partner in Polaris
- Managing Partner, Polaris
- Managing Partner, Polaris' Boston Office
Amir Nashat, PhD, is a managing partner in Polaris' Boston office. Amir joined Polaris in April 2002 and focuses on investments in health care, consumer products, and energy.
Amir currently represents Polaris as a director of AgBiome, a Tyr Pharmaceuticals, BIND Therapeutics, Fate Therapeutics, Promedior Pharmaceuticals, Receptos (NASDAQ: RCPT), Scholar Rock, Selecta Biosciences, and Sun Catalytix. Additionally, Amir has served as a director of Adnexus Therapeutics (acquired by Bristol Myers Squibb), Athenix Corporation (acquired by Bayer), Avila Therapeutics (acquired by Celgene), Living Proof, Pervasis Therapeutics (acquired by Shire Pharmaceuticals) and served as a Board Observer of GI Dynamics (GID.AX). In addition to his role as an investor, Amir has also served as the initial CEO of Living Proof (known as Andora at the time), and Sun Catalytix Corporation.
Prior to joining Polaris, Amir completed his PhD as a Hertz fellow in chemical engineering at the Massachusetts Institute of Technology with a minor in biology under the guidance of Dr. Robert Langer. Amir also earned both his master of science and bachelor of science in materials science and mechanical engineering at the University of California, Berkeley.
Amir serves on the Mass General Brigham Innovation Fund and is a catalyst of the Deshpande Center for Technological Innovation at MIT. He previously served on the board of the New England Venture Capital Association. He has been named to the Forbes Midas list of "Top 100 Venture Capitalists."
Job Titles:
- Operating Partner at Cressey and Company
Andy Hurd is an operating partner at Cressey and Company, previously serving as chief executive officer of Mede Analytics, bringing with him over 25 years of experience in health care IT, including product and market innovation, as well as strategic partnerships.
Andy was CEO of Epocrates (NASDAQ: EPOC), which was purchased by athenahealth (NASDAQ: ATHN). Prior to Epocrates, Andy served as chair and CEO of Carefx, which was acquired by Harris Corporation (NYSE: HRS) in 2011. During his six-year tenure at Carefx, the company achieved strong growth in revenue, income, and shareholder value. Before Carefx, Hurdheld senior management positions at WebMD, LLC (NASDAQ: WBMD) and QuadraMed Corporation.
Andy holds a bachelor's degree in business administration from Northern Arizona University, and he is a member of the board of directors of Ability Networks and the Cleveland Clinic Innovations Advisory Board.
Job Titles:
- Accreditation Manager
- Neurology
Job Titles:
- Advisor
- Director
- Director and Advisor for Corporate and Non - Profit Boards
Barbara Lubash is a director and advisor for corporate and non-profit boards. She serves on the boards of Advanced ICU Care, CareConnectMD, Clew Medical, and the Solve ME/CFS (Chronic Fatigue Syndrome) Initiative. Barbara is a member of the Mass General Brigham Innovation advisory board, the health policy and management executive council of the Harvard T.H. Chan School of Public Health and is an advisor to STEMAdvantage.
In her prior careers as a health care executive and venture capitalist, Barbara led and advised innovative health care and service organizations. She was co-founder and managing director of Versant Ventures, and before that, a venture partner at Crosspoint Ventures. Prior corporate boards include CodeRyte (acquired by 3M), Cogent Healthcare (acquired by Sound Physicians), Concerto HealthCare, Redbrick Health (Virgin Pulse), Titan Health (acquired by USPI), and Vantage Oncology (acquired by McKesson). She was board chair of the California HealthCare Foundation, where she led the early development of its PRI impact investment strategy (Innovation Fund). She was also a senior executive at PacifiCare Health Systems (acquired by United) and Private Healthcare Systems, a national PPO, and held management roles at Hewlett Packard and the Harvard Community Health Plan (Harvard Pilgrim). She received a bachelor of science from Tufts University, and a masters in health policy and management from Harvard University. She has completed board of directors training at Stanford Directors College.
Job Titles:
- Member of the Board of Directors
- CEO, Pivotal Design Labs
Ben Pless has over 25 years of experience developing and bringing to market implantable medical devices and is currently CEO of Pivotal Design Labs, a medical device consulting organization. Most recently he was President and CEO of Autonomic Technologies, developing a minimally invasive neurostimulator to treat severe headache. Prior to that he was the Chief Operating Officer and Chief Technical Officer of NeuroPace, a privately-held company developing electronic implantable devices for the treatment of epilepsy. Before joining NeuroPace in 2000, he was responsible for worldwide development activities for the Cardiac Rhythm Management Division of St. Jude Medical, Inc. Mr. Pless previously served as Vice President of product development for Ventritex, Inc. and General Manager of its Maven Capacitors division until the sale of the company to St. Jude Medical in 1997. He was a founder of Ventritex where he was instrumental in the development of one of the first implantable cardiac defibrillators. His career began at Intermedics, where he was a development engineer for implantable pacemakers.
Mr. Pless is a member of the board of directors of several start-up medical device companies and regularly provides consulting services to the venture capital community. Mr. Pless received a B.S.E.E. from the Massachusetts Institute of Technology and attended graduate school at Rice University. He is a named inventor on over 100 patents and patent applications.
Job Titles:
- Professor of Medicine, Harvard Medical School
Job Titles:
- David Glendenning Cogan Professor and Chair of the Department of Ophthalmology, Harvard Medical School
Job Titles:
- Professor of Bioinspired Engineering, Harvard Medical School
Job Titles:
- Professor of Surgery, Harvard Medical School
Job Titles:
- Member of the Innovation Team
- Managing Director, Bain Capital
- Managing Director, Bain Capital Life Sciences Fund
Dr. Adam Koppel rejoined Bain Capital in 2016 as managing director of the Bain Capital Life Sciences Fund. He had initially joined Bain Capital Public Equity in 2003, where he was a leader within the health care sector until mid-2014. During mid-2014 to mid-2016, Dr. Koppel was at Biogen, where he served as executive vice president of corporate development and chief strategy officer. He sits on the board of directors of PTC Therapeutics (NASD: PTCT) and Trevena (NASD:TRVN).
Prior to joining Bain Capital in 2003, Dr. Koppel was an associate principal at McKinsey & Co in New Jersey, where he served a variety of health care companies. Dr. Koppel received a medical degree and a PhD in neuroscience from the University of Pennsylvania School of Medicine. He also received a master of business administration from The Wharton School at the University of Pennsylvania, where he was a palmer scholar. He graduated magna cum laude from Harvard University with a bachelor of arts and master of arts in history and science.
Job Titles:
- Member of the Innovation Team
- MIS
- Physician and Chief Medical Information Officer for Health Information Innovation and Integration at Brigham
Dr. Adam Landman is an emergency physician and chief medical information officer for health information innovation and integration at Brigham and Women's Hospital. Dr. Landman holds degrees in information systems and health care policy from Carnegie Mellon University and a medical degree from UMDNJ - Robert Wood Johnson Medical School. After medical school, he trained in emergency medicine at the University of California, Los Angeles, and completed the RWJ Foundation Clinical Scholars fellowship in health services research, where he worked on qualitative and quantitative studies on the adoption of health information technology in the emergency department and pre-hospital settings.
Dr. Landman focuses on the innovative use of information technology to improve health care delivery. He steered a three-year, $7 million, custom software development project to move Brigham and Women's emergency department clinicians from paper-based to electronic documentation. He is currently responsible for clinical oversight of the implementation and integration of a new hospital laboratory system, as well as multiple projects related to a new enterprise implementation and health information innovation programs.
The Landman laboratory has received grant funding to build and pilot a mobile app for capturing and storing clinical images; use high-fidelity medical simulation centers to evaluate health information technology in a controlled, safe environment; and build an improved electronic medication administration and reconciliation system. Dr. Landman welcomes the opportunity to work with students and residents interested in clinical and research informatics.
Job Titles:
- Member of the Innovation Team
- CEO and a Board Member, Voyager Therapeutics
- CEO of Voyager
- CEO, Voyager Therapeutics
Dr. Alfred Sandrock has been CEO of Voyager and a board member since 2022. Dr. Sandrock joined Voyager, following a prolific career in biopharmaceutical drug development, in which he spent 23 years at Biogen, where he identified and developed novel therapies for a variety of serious diseases. While at Biogen, Dr. Sandrock served in positions of increasing responsibility, culminating in his service as executive vice president of research and development. He also served as chief medical officer and held a seat on the Biogen executive committee. Over the course of his tenure, he led the discovery and development, and regulatory approval of numerous medicines including: ADUHELM™, PLEGRIDY®, SPINRAZA®, TECFIDERA®, and TYSABRI®. Dr. Sandrock earned a bachelor's degree in human biology from Stanford University, a medical degree from Harvard Medical School, and a PhD in neurobiology from Harvard University. He completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in neuromuscular disease and clinical neurophysiology at Massachusetts General Hospital.
Job Titles:
- Member of the Innovation Team
- Cardiologist
- Cardiologist, Geneticist, and Developmental Biologist
Dr. Calum MacRae is a cardiologist, geneticist, and developmental biologist. He is Professor of Medicine at Harvard Medical School, Director of One Brave Idea at Brigham and Women's Hospital, an Associate Member at the Broad Institute and a Principal Faculty member at the Harvard Stem Cell Institute. His research is focused on understanding the fundamental mechanisms of disease, using human studies and complementary systems-level modeling in model organisms and stem cells. He co-leads a national drug discovery consortium focused on environmental threats, he is the Principal Investigator of the Apple Health Study and has extensive experience in the integration of novel tools and devices at the interface between biology and technology. He is a co-founder of Atman Health and Tanaist Bio and is a board member at TMA Precision Health and LifeMD. His clinical interests include general cardiology, genomic medicine, innovation in phenotyping, and the redesign of clinical care.
Job Titles:
- Member of the Graduate Medical Education Leadership Team
- Associate DIO
Job Titles:
- Member of the Graduate Medical Education Leadership Team
- Associate DIO
- Trainee Orientation, Retreats and Town Meetings
Job Titles:
- President, the Braxton Company and Innovation Growth
Job Titles:
- Physician, Faculty, and Investor
Job Titles:
- Professor of Pathology, Harvard Medical School
Job Titles:
- Radiology
- Oral and Maxillofacial Surgery ( Includes Dentistry )
- Pathology
- Senior Accreditation Manager
Job Titles:
- Founder & Managing Partner, Arboretum Ventures
Job Titles:
- Chief, Plastic Surgery at Massachusetts General Hospital
Job Titles:
- David Glendenning Cogan Professor and Chair of the Department of Ophthalmology, Harvard Medical School
Job Titles:
- Partner and Managing Director, Santé Ventures
Job Titles:
- Senior Vice President, GSK
Job Titles:
- Member of the Graduate Medical Education Leadership Team
Job Titles:
- Chief Academic Officer, Brigham and Women 's Hospital
Job Titles:
- Operating Partner and Senior Advisor, the Riverside Company
Job Titles:
- Chief Scientific Officer and James and Patricia Poitras Chair in Psychiatry, McLean Hospital
Job Titles:
- Coordinator Retreats
- Program Director Workshops
Job Titles:
- Chief Commercial Officer, Everly Health
Job Titles:
- Professor of Medicine, Harvard Medical School
Job Titles:
- Psychiatrist - in - Chief, Massachusetts General Hospital
Job Titles:
- Professor of Surgery, Harvard Medical School
Job Titles:
- Chief Scientific Officer, Mass Eye and Ear
Job Titles:
- Professor of Neurology and Neuroscience, Harvard Medical School
Job Titles:
- Associate Professor, Harvard Medical School
Job Titles:
- Managing Partner, Chief Operating Officer, and Innovation Growth Board Chairman, SV Health Investors
Job Titles:
- Co - Founder, Health Advances
Job Titles:
- Partner, Third Rock Ventures
Job Titles:
- Chief Academic Officer, Massachusetts General Hospital
Job Titles:
- Director of the Genetics and Aging Research Unit and Vice - Chair of Neurology, Massachusetts General Hospital
Job Titles:
- Physician and Entrepreneur
Job Titles:
- Member of the Graduate Medical Education Leadership Team
- Education Committee
See the director and accreditation manager assignments for oversight of specific programs/departments by the GME directors and accreditation managers.
Job Titles:
- Chief Innovation Officer, GE and CEO, GE Ventures